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Vitamin B12 and folate tests: the ongoing need to determine appropriate use and 
public funding. 
Cameron D Willis, Michael P Metz, Janet E Hiller and Adam G Elshaug 
Introduction 
Criteria have been developed for assessing the safety, effectiveness and cost-
effectiveness of new and emerging health interventions. Additional challenges exist in 
identifying opportunities for reducing the use of existing health technologies or 
procedures that are potentially overused, (cost-) ineffective or unsafe.(1) Criteria have 
been proposed to ‘flag’ technologies that might warrant further investigation under 
quality improvement programs.(1) These criteria are: new evidence, geographic 
variations in use; provider variations in care; technology development; temporal 
variations in volume; public interest or controversy; consultation; assess new 
intervention and displace old; leakage; legacy items; use not in accordance with 
clinical guidelines; or nomination from clinical groups. Following such a nomination 
by members of the clinical laboratory community regarding B12 and folate tests, we 
sought to determine if these tests met other criteria. This article intends to encourage 
debate and discussion around the appropriate use of these tests.  
 
Diagnosing vitamin B12 and/or folate deficiencies is difficult. There are diverse 
symptoms (such as malaise, fatigue, and neurological symptoms) and signs (including 
megaloblastic anaemia and cognitive impairments).  Defining target ‘conditions’ is 
therefore difficult.  Tests include full blood count and blood film examination, serum 
B12, serum folate, and red cell folate (RCF) assays, as well as examination of 
metabolic markers such as methylmalonic acid (MMA) and homocysteine (Hcy).  
Untreated B12 deficiencies may cause serious health problems, including permanent 
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neurological damage (which may occur with low serum B12 without haematological 
changes).  Maternal folate deficiencies have been associated with neural tube defects 
in infants.  Potential B12 or folate deficiencies therefore need to be appropriately 
investigated and managed.  
 
The utility of a diagnostic test is influenced in part by its precision (the ability of a test 
to faithfully reproduce its own result) and its diagnostic accuracy (ability to 
discriminate between a target condition and health).  Evidence (as outlined below) 
suggests serum B12 tests have poor discriminative ability in many situations, while the 
most useful folate investigation remains debated. 
 
The only systematic review and meta-analysis of the diagnostic accuracy of serum B12 
tests (conducted by members of our group) suggests these tests often misclassify 
individuals as either B12 deficient or B12 replete.(2)  These findings are consistent 
with other reports in the literature, such as noted by Stabler who state “…false 
negative and false positive values are common (occurring in up to 50% of tests) with 
the use of the laboratory reported lower limit of the normal range as a cutoff point for 
deficiency”.(3)  Stabler also comments that there ‘…is often poor agreement when 
samples are assayed by different laboratories or with the use of different methods”.(3)  
Carmel notes “widespread CBLA [competitive-binding luminescence assay] 
malfunction”, with assay failure rates of 22% to 35% (interference due to intrinsic 
factor antibodies may explain some of this variation).(4)  While Carmel suggests that 
“falsely normal cobalamin concentrations are infrequent in patients with clinically 
expressed deficiency”, he notes challenges in diagnosing ‘subclinical deficiency’ 
(mild metabolic abnormalities without clinical signs or symptoms).(5)  Assessing this 
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evidence base is complicated by a lack of a universally accepted gold standard, 
difficult to define target conditions and variable clinical presentations, and variable 
cut-off values used to define deficiency.  
 
For investigating folate status, RCF assays are thought to be less susceptible to short 
term dietary intake than are assays for serum folate.  However according to Galloway 
and Rushworth the RCF assay “is more complex to perform than the serum folate 
assay and requires more steps in sample handling before analysis, and this may be one 
of the reasons why the precision of the [RCF] assay is less than that of the serum 
folate assay”.(6) 
 
As discussion continues over which folate test is preferable, new evidence relating to 
the prevalence of folate deficiencies in countries with mandatory food fortification 
has shifted the focus toward the need to perform any folate investigations in these 
jurisdictions.  In Australia, prevalence estimates from a sample of inpatients and 
outpatients suggest folate deficiency now stands at 0.5%, an 85% reduction in 
absolute numbers from April 2009.(7)  While there is currently no evidence to suggest 
that the prevalence of folate deficient megaloblastic anaemia has been reduced, the 
low frequency of low serum RCF test results in folate fortified countries supports the 
perspective that there is “no longer any justification in ordering folate assays to 
evaluate the folate status of patients”.(8)  
 
Another proposed ‘flag’ for quality improvement occurs when older technologies 
become superseded by more effective methods.(1)  For example, over time multiple 
technologies for analysing vitamin B12 status have become available, including assays 
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for measuring holotranscobalamin (HoloTC- bioavailable B12), as well as metabolic 
markers such as MMA and Hcy. However, like all tests, these are imperfect: HolotTC 
is expensive, not routinely available, itself reliant on poorly defined serum B12 
reference ranges, and yet to be confirmed as a superior test than the serum B12 assay. 
Hcy measurement is subject to artefactual increases due to collection practices, and 
variable reference ranges. The availability of MMA tests is restricted to some clinical 
and research laboratories. As a result, the optimal procedure for measuring B12 is 
unclear.  As previously noted, while a number of approaches exist for assessing folate 
status (including RCF and serum assays), there is currently no consensus on the most 
appropriate laboratory investigation process. 
 
Australian Medicare utilisation data demonstrate substantial growth in the use of item 
number 66602, which relates to the combined use of serum B12 and folate tests. 
Between financial years 2000/2001 to 2010/2011, use increased from 1,082 services 
per 100,000 population to 7,243 services per 100,000 population (21.78% average 
annual growth rate).(9) Over the same period, spending on pathology services overall 
grew at an average annual rate of 6.3%. 
  
Geographic variation is also present, with reimbursement for item 66602 ranging 
from 2,329 per 100,000 population (Northern Territory) to 8,561 per 100,000 
population (New South Wales).(9) While some of this variation may be due to 
demographic differences and traditionally under-serviced populations (e.g. Indigenous 
Australians), the substantial differences in temporal and geographic use serves to raise 
more questions about appropriate use of these tests, and whether or not under or over 
use is present.  
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Available guidelines related to the use of vitamin B12 and folate tests also vary widely 
in their recommendations. While some recommend B12 and folate tests as screening 
tools in commonly encountered illnesses such as dementia, others suggest restricting 
testing to patients who have already undergone pre-test investigations (such as full 
blood examinations; however we note that neurological damage may occur in patients 
with low serum B12 levels and without haematological changes).(10, 11) Guidelines 
may differ on key recommendations, such as the preferred first line investigation for 
establishing folate status, while others question the utility of folate investigations at 
all in folate fortified jurisdictions.(12-14) 
 
With wide variability in guideline recommendations, and with few appearing to 
consider the diagnostic accuracy of B12 or folate tests, determining the extent to which 
services have ‘leaked’ beyond their clinical indications is difficult; however an 
example of possible leakage is available. Bayram et al. note that use of serum B12 
tests in patients presenting with weakness and tiredness is not supported by any 
available guidelines.(15) Despite this, a large study of general practitioners indicates 
that from 2002-2008, their use of serum B12 tests in patients presenting with weakness 
and tiredness increased by 105%.(15) 
 
Discussion 
Tests for investigating the status of vitamin B12 and folate levels have become widely 
used in clinical practice. Yet existing evidence suggests that the diagnostic accuracy 
of serum B12 tests is difficult to determine and may be highly variable.  While other 
tests are available for investigating B12 and/or folate deficiency (such as HoloTC, 
MMA and Hcy), the diagnostic accuracy of these tests is also contested.  Challenges 
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in examining the diagnostic accuracy of serum B12 tests include highly variable 
clinical presentations, lack of a gold standard and inconsistent cut-off values used to 
define deficiency.  While the most useful test for investigating folate status remains 
debated (serum or RCF), mandatory folate fortification in Australia may question the 
ongoing use of these tests at all.  
 
Temporal variation in use and geographic differences in how these tests are employed 
are both evident in Australian data.  Moreover, available clinical guidelines are highly 
inconsistent in their recommendations. Collectively, the issues of test accuracy, wide 
variability in test use, and inconsistent guideline recommendations suggest that the 
use of vitamin B12 and folate tests is an area with much scope for quality 
improvement.  
 
To improve the use of these tests, further assessment is needed that examines the 
complexity associated with clinical decision making, and the various factors 
influencing why doctors request these tests. The decision to request an investigation 
such as a B12 or folate test may be driven by a range of factors, including ease of use, 
cost, absence of significant patient risk, the perceived need to respond to patient 
requests, lack of appreciation of the diagnostic accuracy of the tests, or ready 
availability of results.(16)  Understanding how these factors influence the use of B12 
and folate tests may be best acquired through direct consultation with key stakeholder 
groups such as general practitioners, pathologists, specialists and consumers, and is a 
critical step in advancing the assessment of these tests.  
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